scholarly journals Impact of body mass index on atrial fibrillation ablation using cryoballoon: procedural data and clinical outcomes

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
L Urbanek ◽  
S Chen ◽  
S Bordignon ◽  
N Tsianakas ◽  
F Bologna ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Body Mass Index ◽  
Pulmonary Vein ◽  
Body Mass ◽  
Pulmonary Vein Isolation ◽  
Clinical Success ◽  
Cryoballoon Ablation ◽  
Group 3 ◽  
The Impact

Abstract Background The impact of body mass index (BMI) on atrial fibrillation (AF) ablation using cryoballoon (CB) has been seldom reported. Purpose To evaluate the impact of BMI on procedural data as well as the clinical efficacy and safety character of using CB. Methods Symptomatic AF patients (paroxysmal / persistent AF) with BMI ≥25 who underwent CB based pulmonary vein isolation (PVI) were enrolled. CB PVI was performed using the second generation CB (CB 2, 28mm), with 4min based freeze protocol and bonus freeze delivery in case of time-to-isolation (TTI) >75 sec. All procedures were performed under conscious sedation. Procedural endpoint was electrical pulmonary vein isolation. Clinical success was defined as no recurrence of AF/atrial tachycardia (AT). Results Data from 600 consecutive patients were collected. Three groups defined: BMI 25–29 (Group 1, G1 n=337); BMI 30–34 (Group 2, G2 n=149); BMI ≥35 (Group 3, G3 n=114). Patients in Group 3 were younger (G1: 67±11 y; G2: 68±10y G3 62±11y; p<0,001) and presented bigger LA (G1 39,5±4,9 mm; G2: 41,6±5,5; G3 42,4±5,1; p<0,001). Most of the patients presented with PAF (G1: 59,3% G2: 57,7% G3: 54,4%). Among 2342 Targeted PVs, 2332 (99,6%) were isolated using solely the CB (G2: one procedure was abolished due to failed aortic puncture during transseptal access; G3: one PVI was not completed due to PNP; 6 touch up RF ablation in G1 and 2 in G3). Procedure time (G1:58,45 min; G2: 60,44 min; G3 63,19 min) and fluoroscopy time (G1: 9,3 min; G2: 9,5 G3: 10,6 min) were comparable among the groups. PN Injury was the main recorded complication: 20/600 (2,6%) patients with a transient PN palsy (PNP) and 6/600 (1%) with a persistent PNP. No sedation related complication was recorded. Follow up survival curve analysis after one year revealed a favorable follow up in G1 (78,4%) and G2 (82,5%) compared to G3 (66,5%) (G1 Vs G3 p: 0,002 G2 vs G3 p=0,008, G1 vs G2 p=0,47). The influence of BMI on the follow up was confirmed in the subgroup of patients with paroxysmal AF but not in patients presenting persistent AF. Conclusions Cryoballoon ablation in obese patients is feasible and associated with a relatively low complication rate. BMI plays a role in predicting recurrences especially in patients presenting with paroxysmal AF. Funding Acknowledgement Type of funding source: None

scholarly journals Clinical success of cryoballoon pulmonary vein isolation in patients with atrial fibrillation

2019 ◽  
Vol 7 (4S) ◽  
pp. 6-14
Author(s):  
T. Y. Chichkova ◽  
S. E. Mamchur ◽  
E. A. Khomenko
Keyword(s):  
Atrial Fibrillation ◽  
Pulmonary Vein ◽  
Pulmonary Vein Isolation ◽  
Direct Current ◽  
Clinical Success ◽  
Persistent Atrial Fibrillation ◽  
Cryoballoon Ablation ◽  
Clinical Effects ◽  
Rf Ablation

Aim. To estimate the clinical success of cryoballoon pulmonary vein isolation (PVI).Methods.230 patients (males: 49.6%, mean age 57 (53; 62) with symptomatic paroxysmal and persistent atrial fibrillation (AF) resistant to antiarrhythmic therapy were included in a single-center prospective study. The patients were randomized into 2 groups to undergo either cryoballoon ablation (n = 122) or radiofrequency (RF) (n = 108) ablation. Both groups were comparable in baseline parameters. The follow-up period was 12 months. Clinical outcomes were estimated with the use of a three-stage scale. The rates of cardiovascular rehospitalizations, direct-current cardioversions and repeated ablations during were estimated within the follow-up. The quality of life (QoL) in the cryoablation group was measured using the AFEQT scale.Results.77% (n = 94) of patients in the cryoballoon ablation group and 71.3% (n = 77) of patients in the RF group (р = 0.71) demonstrated reported the optimal clinical effects. Both groups, cryo ablation and RF ablation, had similar rates of cardiovascular hospitalizations (23.8 vs 28.7%, OR 0.8, 95% CI 0.4–1.4; р = 0.39), direct-current cardioversions (12.3 vs 17.6%, OR 0.7, 95% CI 0.3–1.4; р = 0.26) and repeated ablations (9.8–11.1%, OR 0.9, 95% CI 0.4–2.0; р = 0.75). The patients treated with cryoballoon as opposed to RF ablation had significantly more successful usage of “pill-in-pocket” strategy – 14.8 vs 6.5% (OR 2.5, 95% CI 1.01–6.2; р = 0.04). Significant improvements of the QoL parameters with strong size effect have been found in the cryoablation group, i.e. global score (GS) increased by 8.9±6.9 (95% CI 6.6–10.1; dCohen 1.2; р<0.001), symptoms (S) – by 8.3±7.9 (95% CI 4.2–8.8; dCohen 1.5; р<0.001), daily activities (DA) – by 10.0±6.9 (95% CI = 6.4–10.6; dCohen 0.9; р<0.001), treatment concerns (TC) – by 5.5±6.0 (95% CI 6.3–9.2; dCohen 1.2; р<0.001) and treatment satisfaction (TS) – by 5.5±6.0 (95% CI 5.4–9.8; dCohen 0.9; р<0.001).Conclusion.The both catheter-based technologies had comparable clinical success. Cryoablation was characterized by improvement in all QoL parameters based on the AFEQT score.

Impact of body mass index on outcomes in European patients with atrial fibrillation: the ESC EHRA EORP Atrial Fibrillation General Long-Term registry (AFGen LT)

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
G Boriani ◽  
M Proietti ◽  
C Laroche ◽  
L Fauchier ◽  
F Marin ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Body Mass Index ◽  
Body Mass ◽  
Large Cohort ◽  
Funding Source ◽  
Increased Risk ◽  
Underweight Patients ◽  
The Impact

Abstract Introduction The impact of body mass index (BMI) on outcomes in patients with atrial fibrillation (AF) has been largely debated. Aims To describe the relationship between BMI categories and clinical outcomes in a large cohort of European AF patients. Methods We included all AF patients with available baseline BMI and creatinine clearance and 1-year follow-up data enrolled in the EORP-AF General Long-Term Registry. Outcomes considered were: i) a composite of any thromboembolic event (TE)/acute coronary syndrome (ACS)/cardiovascular (CV) death; ii) CV death; iii) all-cause death. Results A total of 7,759 patients were included in this analysis. Of these, 55 (0.7%) were underweight, 2,074 (26.7%) were normal weight, 3,170 (40.9%) were overweight, 1,703 (21.9%) were obese and 757 (9.8%) were severe obese. Mean age was progressively lower across the categories (p&lt;0.0001), with proportion of patients aged≥75 years also progressively lower (52.7% in underweight to 19.4% in severe obese patients; p&lt;0.001). Both underweight (41.8%) and severe obese (25.0%) patients were more likely symptomatic (p&lt;0.001). Mean CHA2DS2-VASc score was higher in underweight patients (p=0.0325). Use of any oral anticoagulant therapy was progressively higher across the BMI categories (p&lt;0.001). At 1-year follow-up the rate of all outcomes considered were highest for underweight patients and lowest in severe obese [Figure 1]. On univariate Cox regression analysis, being underweight was consistently associated to a higher risk for all outcomes, while increasing of weight categories was associated with progressively lower risk for adverse outcomes. After full adjustment with clinical and pharmacological characteristics, no effect of higher BMI classes was found for any outcome, but an independent association with an increased risk of CV death and all-cause death was seen for underweight patients (Table 1). Conclusions In a large cohort of European AF patients a progressively lower rate of outcomes was found across increasing BMI classes. After full adjustments, no significant association was found between the higher BMI classes and outcomes. Underweight was associated with an increased risk for CV death and all-cause death. Figure 1. Outcomes at 1-year Follow-up Funding Acknowledgement Type of funding source: Private company. Main funding source(s): Since the start of EORP programme, several companies have supported it with unrestricted grants

scholarly journals Impact of body mass index on the outcome of catheter ablation of atrial fibrillation

Heart ◽  
2018 ◽  
Vol 105 (3) ◽  
pp. 244-250 ◽  
Author(s):  
Benedict M Glover ◽  
Kathryn L Hong ◽  
Nikolaos Dagres ◽  
Elena Arbelo ◽  
Cécile Laroche ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Body Mass Index ◽  
Catheter Ablation ◽  
Body Mass ◽  
Lifestyle Modification ◽  
Weighted Analysis ◽  
The Impact ◽  
Baseline Bmi ◽  
Af Recurrence

ObjectivesThe association between obesity and atrial fibrillation (AF) is well-established. We aimed to evaluate the impact of index body mass index (BMI) on AF recurrence at 12 months following catheter ablation using propensity-weighted analysis. In addition, periprocedural complications and fluoroscopy details were examined to assess overall safety in relationship to increasing BMI ranges.MethodsBaseline, periprocedural and follow-up data were collected on consecutive patients scheduled for AF ablation. There were no specific exclusion criteria. Patients were categorised according to baseline BMI in order to assess the outcomes for each category.ResultsAmong 3333 patients, 728 (21.8%) were classified as normal (BMI <25.0 kg/m2), 1537 (46.1%) as overweight (BMI 25.5–29.0 kg/m2) and 1068 (32.0%) as obese (BMI ≥30.0 kg/m2). Procedural duration and radiation dose were higher for overweight and obese patients compared with those with a normal BMI (p=0.002 and p<0.001, respectively). An index BMI ≥30 kg/m2 led to a 1.2-fold increased likelihood of experiencing recurrent AF at 12-months follow-up as compared with overweight patients (HR 1.223; 95% CI 1.047 to 1.429; p=0.011), while no significant correlation was found between overweight and normal BMI groups (HR 0.954; 95% CI 0.798 to 1.140; p=0.605) and obese versus normal BMI (HR 1.16; 95% CI 0.965 to 1.412; p=0.112).ConclusionsPatients with a baseline BMI ≥30 kg/m2 have a higher recurrence rate of AF following catheter ablation and therefore lifestyle modification to target obesity preprocedure should be considered in these patients.

scholarly journals Left atrial diameter, CHA2DS2-VASc score and type of atrial fibrillation predict pulmonary vein isolation outcome

2021 ◽  
Author(s):  
Ruzica Jurcevic ◽  
Lazar Angelkov ◽  
Velibor Ristic ◽  
Dejan Vukajlovic ◽  
Petar Otasevic ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Pulmonary Vein ◽  
Pulmonary Vein Isolation ◽  
Left Atrial ◽  
Clinical Success ◽  
Quantitative Measure ◽  
Clinical Failure ◽  
Ordinal Logistic Regression Analysis

Abstract Purpose Pulmonary vein isolation (PVI) is the most effective treatment strategy for atrial fibrillation (AF). This study evaluated Pulmonary Vein Isolation Outcome Degree (PVIOD) as a new semi-quantitative measure for PVI success after a 7-year follow-up and determined predictors associated with PVIOD.Methods We enrolled 117 patients with symptomatic AF who underwent PVI and after a 7-year follow-up applied PVIOD with 4 possible outcomes. PVIOD 1 group included patients with successful single PVI. PVIOD 2 group included patients with efficacy after ≥ 2 re-PV isolation and/or additional substrate modification (ASM). PVIOD 3 group contained subjects with clinical success after PVI±ASM. Patients with procedural and clinical failure were in PVIOD 4 group.Results In multivariate ordinal logistic regression analysis PVIOD was independently associated with longstanding persistent AF with paroxysmal AF as referent category: odds ratio (OR) 4.1, 95% confidence interval (95% CI) 1.3-12.8 (P=0.014), left atrial (LA) diameter: OR 1.2, 95% CI 1.1-1.3 (P<0.001) and CHA2DS2-VASc score: OR 1.5, 95% CI 1.0-2.2 (P=0.039). LA size, CHA2DS2-VASc score and AF type predicted 7-year probability for procedural and procedural with clinical failure. LA diameter >41mm (AUC 0.741, 95% CI 0.6-0.8, P<0.001) and CHA2DS2-VASc score ≥2 (AUC 0.718, 95% CI 0.6-0.8, P<0.001) predicted long-term procedural and clinical failure. Conclusion PVIOD is a new classification for PVI success. LA diameter, CHA2DS2-VASc score and AF type are independently associated with PVIOD and predict procedural and procedural with clinical failure after the 7-year follow-up. LA diameter >41mm and CHA2DS2-VASc score ≥2 predict long-term PVI failure.

scholarly journals Impact of chronic mitral regurgitation on 3D atrial size and mechanics. Insights from the prospective 3D-PRIME study

2021 ◽  
Vol 42 (Supplement_1) ◽  
Author(s):  
D Cramariuc ◽  
A Valeur ◽  
R M Persson ◽  
C E Berg-Hansen ◽  
S Urheim
Keyword(s):  
Atrial Fibrillation ◽  
Body Mass Index ◽  
Mitral Regurgitation ◽  
Pulmonary Vein ◽  
Body Mass ◽  
Mitral Annulus ◽  
University Hospital ◽  
Flow Profile ◽  
Diastolic Velocity ◽  
The Impact

Abstract Background Chronic mitral regurgitation (MR) leads to progressive left atrial (LA) dilation. Its relative contribution to 3-dimensional (3D) LA structural and functional remodelling and the impact of concomitant clinical and hemodynamic factors, has been less explored. Aims To assess 3D LA size and mechanics, as well as mean LA pressure estimated from the pulmonary vein flow, in relation to chronic MR severity. Methods In the prospective 3D-PRIME (3D Echocardiography and Cardiovascular Prognosis in Mitral Regurgitation) study, 46 patients with chronic MR (69±13 years, body mass index (BMI) 26.2±4.3kg/m2, 50% women, 26% with atrial fibrillation, 30% with severe MR) recruited at one heart valve center were investigated with 2D and 3D transthoracic and transesophageal echocardiography. MR severity was quantified by the regurgitant volume (RV) and MR classified as organic, atrial functional or ventricular functional, as by current recommendations. LA size was measured by 3D maximum volume (LAV) indexed for body surface area (LAVI), LA mechanics by 3D peak relative increase in longitudinal volume in the reservoir phase (Sr), and mitral size by 3D annulus area and total leaflet area. Pulmonary vein Doppler flow profile was recorded in both right and left upper veins, and mean LA pressure was estimated from the average pulmonary vein systolic/diastolic velocity time integral ratio. Results Average mitral RV was 38±26ml, LAVI 53ml/m2, and Sr 17±11%. Increased mitral RV correlated with higher LAV and mean LA pressure (Figure 1), larger mitral annulus area (r=0.42) and total leaflet area (r=0.38) (all p&lt;0.01), but not with Sr. In backward stepwise multivariate linear regression analyses, increased LAVI was independently predicted by larger mitral RV, higher age and atrial fibrillation (R2=0.62), higher mean LAP by larger mitral RV, body mass index and atrial fibrillation (R2=0.55), while lower Sr was associated with higher age and atrial fibrillation (R2=0.62) (all p&lt;0.001). Patients with atrial functional MR (30% of the total group) had the largest LAVs and lowest Sr despite slightly lower mitral RV (Figure 2). Conclusion Chronic MR is associated with progressive increase in LA volume, mean LA pressure, and mitral annulus and total leaflet area. While MR is accompanied by low 3D LA longitudinal deformation, impaired LA mechanics is multifactorial and related closely to age and history of atrial arrythmias. FUNDunding Acknowledgement Type of funding sources: Public hospital(s). Main funding source(s): Haukeland University Hospital Figure 1 Figure 2

scholarly journals Impact of comorbidities and ablation strategy on outcome after pulmonary vein isolation with cryo-balloon in patients with non- paroxysmal atrial fibrillation

2021 ◽  
Vol 42 (Supplement_1) ◽  
Author(s):  
A Berkowitsch ◽  
J Hutter ◽  
S Zaltsberg ◽  
M Tomic ◽  
P Kahle ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Pulmonary Vein ◽  
Pulmonary Vein Isolation ◽  
Randomized Study ◽  
Term Outcome ◽  
Long Term Outcome ◽  
The Impact ◽  
Improved Outcome

Abstract Background Presence of several comorbidities in patients with atrial fibrillation is well known, but impact of them on outcome after pulmonary vein isolation with cryo-balloon is not enough investigated. First aim of the study was analysis of the impact of comorbidities on long term outcome after PVI with cryo-balloon new generation (CBA) and secondary goal was evaluation of the impact of additional posterior roof ablation (PRA) in these patients. Methods Patients with non-paroxysmal AF ablated with CBA in our institution since May 2012 and completed follow up &gt;3 months were enrolled in the study. The history of AF, cardiac comorbidities (CAD, Non ischemic-cardiomyopathy, heart insufficiency, right ventricular dysfunction) diabetes mellitus, and renal failure were assessed at admission, all patients received echocardiographic examination and blood test. After a single trans-septal access and PV angiography PVI was performed using a 28-mm CBA. Mapping of PV signals before, during, and after each cryo application was performed with a 3F lasso catheter. The procedural endpoint after PVI was defined as complete elimination of all fragmented signals at the PV antrum with verification of entrance and exit block. In some patients PRA was performed additionally to PVI at discretion of physician. The primary endpoint of this study was the first documented recurrence of atrial tachyarrhythmia (&gt;30 sec.), hospitalization due to cardio-vascular cause, re-do procedure or re-administration of anti-arrhythmic drugs. Results Among 560 patients 78 (13.9%) had no comorbidity and 299 (53.4%) were lasted with &gt;1 comorbidity. A total of 260 (46.4%) recurrences were obtained within median follow up of 28 (12–57) months. Female gender, long time from first diagnosis &gt;12 months and cardiac comorbidity were revealed to be independent predictors for long term recurrences whereas additional PRA performed in 176 pts independently improved outcome (61.9% vs 49.7%). Conclusion Cardiac comorbidities increased probability of post ablation recurrences, but performing of additional posterior roof ablation improved outcome in our cohort. These results should be confirmed in multi-center randomized study FUNDunding Acknowledgement Type of funding sources: None.

Sign in / Sign up

Export Citation Format

Share Document